Our findings, suggesting potential adverse target‐mediated effects of TYK2 inhibition on lung cancer and non‐Hodgkin lymphoma, could have important implications for future safety assessment of deucravacitinib and other TYK2 inhibitors in development. This evidence concerns the gene TYK2 and lung cancer.